{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:11Z","timestamp":1792320371248,"version":"4.4.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1007\/s40261-019-00826-0","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T02:02:35Z","timestamp":1563415355000},"page":"805-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-1158","authenticated-orcid":false,"given":"Katherine A.","family":"Lyseng-Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"826_CR1","volume-title":"IDF clinical practice recommendations for managing type 2 diabetes in primary care","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Brussels: International Diabetes Federation; 2017."},{"issue":"Suppl 1","key":"826_CR2","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 9. Pharmacological approaches to glycemic treatment: standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42(Suppl 1):S90\u2013102.","journal-title":"Diabetes Care"},{"key":"826_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12911","author":"B Ahren","year":"2018","unstructured":"Ahren B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig. 2018. https:\/\/doi.org\/10.1111\/jdi.12911.","journal-title":"J Diabetes Investig"},{"key":"826_CR4","unstructured":"Byetta (exenatide) solution for injection in prefilled-pen: EU summary of product characteristics. S\u00f6dert\u00e4lje: AstraZeneca AB; 2018."},{"key":"826_CR5","unstructured":"Byetta (exenatide) injection: US prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2018."},{"key":"826_CR6","unstructured":"Victoza (liraglutide) 6\u00a0mg\/ml solution for injection in pre-filled pen: EU summary of product characteristics. Bagsv\u00e6rd: Novo Nordisk A\/S; 2018."},{"key":"826_CR7","unstructured":"Victoza (liraglutide) injection, for subcutaneous use: US prescribing information. Plainsboro: Novo Nordisk Inc.; 2018."},{"key":"826_CR8","unstructured":"Lyxumia (lixisenatide) 10 and 20 micrograms solution for injection: EU summary of product characteristic. Paris: Sanofi-aventis Groupe; 2017."},{"key":"826_CR9","unstructured":"Adlyxin (lixisenatide) injection, for subcutaneous use: US prescribing information. Bridgewater Sanofi-Aventis U.S. LLC; 2019."},{"key":"826_CR10","unstructured":"Trulicity (dulaglutide) 0.75 and 1.5 mg solution for injection in pre-filled pen: EU summary of product characteristics. Utrecht: Eli Lilly Nederland B.V.; 2018."},{"key":"826_CR11","unstructured":"Trulicity (dulaglutide) injection for subcutaneous use: US prescribing information. Indianapolis: Eli Lilly and Company; 2019."},{"key":"826_CR12","unstructured":"Bydureon 2 mg prolonged-release suspension for injection ([powder and solvent; pre-filled pen and BCise): EU summary of product characteristics. S\u00f6dert\u00e4lje (Sweden): AstraZeneca AB; 2019."},{"key":"826_CR13","unstructured":"Bydureon\u00ae (exenatide extended-release) for injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018."},{"key":"826_CR14","unstructured":"Bydureon\u00ae BCise\u2122 (exenatide extended-release) injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2019."},{"key":"826_CR15","unstructured":"Ozempic (semagutide) 0.25, 0.5 and 1 mg solution for injection in pre-filled pen: EU summary of product characteristics. Bagsv\u00e6rd: Novo Nordisk A\/S; 2018."},{"key":"826_CR16","unstructured":"Ozempic (semaglutide) injection 0.5\u00a0mg\/1\u00a0mg: US prescribing information. Plainsboro: Novo Nordisk Inc.; 2017."},{"issue":"1","key":"826_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"AC Sposito","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LSF, et al. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. https:\/\/doi.org\/10.1186\/s12933-018-0800-2.","journal-title":"Cardiovasc Diabetol"},{"key":"826_CR18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","volume":"108","author":"D Sharma","year":"2018","unstructured":"Sharma D, Verma S, Vaidya S, et al. Recent updates on GLP-1 agonists: current advancements and challenges. Biomed Pharmacother. 2018;108:952\u201362.","journal-title":"Biomed Pharmacother"},{"key":"826_CR19","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","volume":"35","author":"R Gentilella","year":"2019","unstructured":"Gentilella R, Pechtner V, Corcos A, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35:e3070. https:\/\/doi.org\/10.1002\/dmrr.3070.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"826_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s42000-018-0038-0","volume":"17","author":"D Sfairopoulos","year":"2018","unstructured":"Sfairopoulos D, Liatis S, Tigas S, et al. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens). 2018;17(3):333\u201350.","journal-title":"Hormones (Athens)."},{"issue":"3","key":"826_CR21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s12020-014-0373-0","volume":"48","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Gou S, et al. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine. 2015;48(3):794\u2013803.","journal-title":"Endocrine"},{"key":"826_CR22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"826_CR23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Hitke","year":"2017","unstructured":"Hitke ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"826_CR24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.13107","volume":"20","author":"S Unni","year":"2018","unstructured":"Unni S, Wittbrodt E, Ma J, et al. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):468\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"826_CR25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dom.12624","volume":"18","author":"M Yu","year":"2016","unstructured":"Yu M, Van Brunt K, Varnado OJ, et al. Patient-reported outcome. Results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18(4):419\u201324.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"826_CR26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1464-5491.2009.02752.x","volume":"26","author":"JH Best","year":"2009","unstructured":"Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009;26(7):722\u20138.","journal-title":"Diabet Med"},{"issue":"2","key":"826_CR27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2337\/dc10-1119","volume":"34","author":"JH Best","year":"2011","unstructured":"Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34(2):314\u20139.","journal-title":"Diabetes Care"},{"issue":"6","key":"826_CR28","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"826_CR29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"826_CR30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"826_CR31","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417","author":"AJ Ahmann","year":"2017","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2017. https:\/\/doi.org\/10.2337\/dc17-0417.","journal-title":"Diabetes Care"},{"issue":"4","key":"826_CR32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"R Pratley","year":"2018","unstructured":"Pratley R, Aroda V, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"826_CR33","doi-asserted-by":"publisher","unstructured":"Uusinarkaus K, Rodbard HW, Van Gaal L, et al. Semaglutide-induced weight loss is associated with improved health-related quality of life and treatment satisfaction [abstract no. 1020-P]. Diabetes. 2019;68 (Suppl 1). https:\/\/doi.org\/10.2337\/db19-1020-P.","DOI":"10.2337\/db19-1020-P"},{"key":"826_CR34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/PPA.S151736","volume":"12","author":"F Giorgino","year":"2018","unstructured":"Giorgino F, Penformis A, Pechtner V, et al. Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Prefer Adherence. 2018;12:707\u201319.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"826_CR35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","volume":"34","author":"H Nguyen","year":"2017","unstructured":"Nguyen H, Dufour R, Caldwell-Tarr A. Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population. Adv Ther. 2017;34(3):658\u201373.","journal-title":"Adv Ther"},{"issue":"11","key":"826_CR36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s12325-014-0166-0","volume":"31","author":"SS Johnston","year":"2014","unstructured":"Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119\u201333.","journal-title":"Adv Ther"},{"key":"826_CR37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/DMSO.S99732","volume":"9","author":"Q Qaio","year":"2016","unstructured":"Qaio Q, Ouwens MJ, Grandy S, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201\u20135.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7","key":"826_CR38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/dom.12902","volume":"19","author":"C Alatorre","year":"2017","unstructured":"Alatorre C, Fern\u00e1ndez Land\u00f3 L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953\u201361.","journal-title":"Diabetes Obes Metab"},{"issue":"9-a","key":"826_CR39","first-page":"S42","volume":"24","author":"M Heile","year":"2018","unstructured":"Heile M, Wyne K, Billings LK, et al. Cardiovascular outcomes with once-weekly GLP-1 RAs: clinical and economic implications. J Manag Care Spec Pharm. 2018;24(9-a):S42\u201352.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"826_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11892-018-1043-z","volume":"18","author":"G Bahtiyar","year":"2018","unstructured":"Bahtiyar G, Pujais-Kury J, Sacerdote A. Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes. Curr Diabetes Rep. 2018;18(10):92. https:\/\/doi.org\/10.1007\/s11892-018-1043-z.","journal-title":"Curr Diabetes Rep"},{"issue":"11","key":"826_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11886-018-1051-2","volume":"20","author":"Y Li","year":"2018","unstructured":"Li Y, Rosenbilt PD. Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect? Curr Cardiol Rep. 2018;20(11):113. https:\/\/doi.org\/10.1007\/s11886-018-1051-2.","journal-title":"Curr Cardiol Rep."},{"issue":"10","key":"826_CR42","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1093\/cvr\/cvy124","volume":"114","author":"SS Torekov","year":"2018","unstructured":"Torekov SS. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Cardiovasc Res. 2018;114(10):e70\u20131.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"826_CR43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"key":"826_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"1","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;1:1. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"19","key":"826_CR45","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"23","key":"826_CR46","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"13","key":"826_CR47","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"826_CR48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3\u20134","key":"826_CR49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3\u20134):202\u201330.","journal-title":"Rev Diabet Stud"},{"issue":"9-a","key":"826_CR50","first-page":"S14","volume":"24","author":"Y Handelsman","year":"2018","unstructured":"Handelsman Y, Wyne K, Cannon A, et al. Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists. J Manag Care Spec Pharm. 2018;24(9-a):S14\u201329.","journal-title":"J Manag Care Spec Pharm."},{"key":"826_CR51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13300-018-0535-9","volume":"10","author":"I Romera","year":"2019","unstructured":"Romera I, Cebri\u00e1n-Cuenca A, \u00c1lvarez-Guisasola F, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019;10:5\u201319.","journal-title":"Diabetes Ther"},{"key":"826_CR52","first-page":"230624","volume":"2012","author":"F Sun","year":"2012","unstructured":"Sun F, Yu K, Yang Z, et al. Impact of GLP-1 receptors agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res. 2012;2012:230624.","journal-title":"Exp Diabetes Res"},{"issue":"8","key":"826_CR53","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","volume":"37","author":"C Wysham","year":"2014","unstructured":"Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159\u201367.","journal-title":"Diabetes Care"},{"issue":"12","key":"826_CR54","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","volume":"374","author":"KB Filion","year":"2016","unstructured":"Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145\u201354.","journal-title":"N Engl J Med"},{"issue":"11","key":"826_CR55","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40618-017-0698-7","volume":"40","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu A, Scatena S, et al. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. J Endocrinol Investig. 2017;40(11):1251\u20138.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"826_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"826_CR57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsboll","year":"2019","unstructured":"Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2019;20(4):889\u201397.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"826_CR58","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","volume":"54","author":"I Dicembrini","year":"2017","unstructured":"Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933\u201341.","journal-title":"Acta Diabetol"},{"key":"826_CR59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.peptides.2017.08.003","volume":"100","author":"B Pang","year":"2018","unstructured":"Pang B, Zhou H, Kuang H. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy. Peptides. 2018;100:123\u20136.","journal-title":"Peptides"},{"issue":"1","key":"826_CR60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","volume":"37","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225\u201341.","journal-title":"Clin Ther"},{"issue":"5","key":"826_CR61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","volume":"4","author":"TD Filippatos","year":"2013","unstructured":"Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptors on renal function. World J Diabetes. 2013;4(5):190\u2013201.","journal-title":"World J Diabetes."},{"issue":"9","key":"826_CR62","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"826_CR63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","volume":"98","author":"C Alves","year":"2012","unstructured":"Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271\u201384.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"826_CR64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","volume":"48","author":"B Su","year":"2015","unstructured":"Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):107\u201315.","journal-title":"Endocrine"},{"issue":"9861","key":"826_CR65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117\u201324.","journal-title":"Lancet"},{"issue":"1","key":"826_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-016-0155-1","volume":"7","author":"S Kayaniyil","year":"2016","unstructured":"Kayaniyil S, Lozano-Ortega G, Bennet HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther. 2016;7(1):27\u201343.","journal-title":"Diabetes Ther"},{"issue":"9951","key":"826_CR67","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349\u201357.","journal-title":"Lancet"},{"key":"826_CR68","unstructured":"Xultophy (insulin degludec 100 units\/mL + liraglutide 3.6 mg\/mL) solution for injection in pre-filled pen: EU summary of product characteristics. Bagsv\u00e6rd: Novo Nordisk A\/S; 2018."},{"key":"826_CR69","unstructured":"Xultophy 110\/3.6 (insulin degludec and liraglutide injection), for subcutaneous use: US prescribing information. Plainsboro: Novo Nordisk Inc.; 2019."},{"key":"826_CR70","unstructured":"Suliqua 100\/33 (insulin glargine 100 units\/ml +lixisenatide 33 or 50 micrograms\/ml) solution for injection in a pre-filled pen: EU summary of product characteristics. Paris: Sanofi-Aventis Groupe; 2017."},{"key":"826_CR71","unstructured":"Soliqua 100\/33 (insulin glargine and lixisenatide injection), for subcutaneous use: US prescribing information. Bridgewater: Sanofi-Aventis U.S. LLC; 2017."},{"issue":"6","key":"826_CR72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3810\/pgm.2011.11.2508","volume":"123","author":"J Morales","year":"2011","unstructured":"Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med. 2011;123(6):189\u2013201.","journal-title":"Postgrad Med"},{"issue":"2","key":"826_CR73","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejim.2011.11.003","volume":"23","author":"S Madsbad","year":"2012","unstructured":"Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med. 2012;23(2):132\u20136.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"826_CR74","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/ijcp.12361","volume":"68","author":"S Brunton","year":"2014","unstructured":"Brunton S. GLP-1 receptor agonists vs. DDP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557\u201367.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"826_CR75","doi-asserted-by":"crossref","first-page":"e0177646","DOI":"10.1371\/journal.pone.0177646","volume":"12","author":"G Lee","year":"2017","unstructured":"Lee G, Oh SW, Hwang SS, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis. PLoS One. 2017;12(5):e0177646.","journal-title":"PLoS One"},{"issue":"7","key":"826_CR76","doi-asserted-by":"crossref","first-page":"1653\u201364.e1","DOI":"10.1016\/j.clinthera.2016.05.009","volume":"38","author":"CV Spain","year":"2016","unstructured":"Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653\u201364.e1.","journal-title":"Clin Ther"}],"updated-by":[{"DOI":"10.1007\/s40261-020-00892-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000}},{"DOI":"10.1007\/s40261-019-00852-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000}},{"DOI":"10.1007\/s40261-019-00839-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T00:00:00Z","timestamp":1566000000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00826-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-019-00826-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00826-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T11:12:56Z","timestamp":1637838776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-019-00826-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00826-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-019-00852-y","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s40261-020-00892-9","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s40261-019-00839-9","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"18 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-019-00852-y","URL":"https:\/\/doi.org\/10.1007\/s40261-019-00852-y","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-020-00892-9","URL":"https:\/\/doi.org\/10.1007\/s40261-020-00892-9","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2019","order":10,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":11,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-019-00839-9","URL":"https:\/\/doi.org\/10.1007\/s40261-019-00839-9","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.A. Lyseng-Williamson is an employee of Adis International\/Springer Nature, is responsible for the article content and declares no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}